UNASSIGNED: Background and aims: Complete endoscopic resection (CER) of short-segment Barrett's esophagus with @entity1893 ( @entity1893 ) and @entity420 ( @entity420 ) is a precise staging tool and achieves durable disease control. The major drawback is development of post-endoscopic resection esophageal stricture (PERES). No effective therapy to prevent PERES has been described. Viscous @entity4184 slurry (VBS) may have a role in the prevention of PERES by suppressing the post-CER inflammatory process. The study aim was to evaluate the efficacy of VBS for the prevention of PERES. Methods: Prospective data were collected on @entity1 referred for CER of @entity1893 or @entity420 . After January 2012, @entity1 routinely received VBS (two 0.5-mg/2-mL @entity4184 respules mixed with @entity12442 ) twice daily for 6 weeks following each stage of the CER schedule. All @entity1 received high dose proton pump inhibitor therapy for the duration of CER and the following 3 months. @entity1 had no other intervention to prevent PERES.A validated @entity1282 score was used (0-4, no @entity1282 to aphagia). @entity384 was performed for @entity1282 . @entity1 receiving VBS were compared with historical controls. The primary endpoint was the need for dilation. Results: Between January 2008 and January 2015, 104 of 116 eligible @entity1 completed CER. The VBS group (n=29) and non-VBS group (n=75) had similar @entity1 , disease, and procedural characteristics. Dilations were needed in 13.8% vs. 37.3% (P=0.03), with a median of one vs. two procedures (P=0.01), and median @entity1282 score during CER of 0 vs. 1 (P=0.02) in the VBS and non-VBS groups, respectively. No VBS-related adverse events were noted. Conclusion: In this pilot study VBS significantly reduced PERES and shortened the dilation program after CER.

Efficacy of viscous XXXX slurry for prevention of esophageal stricture formation after complete endoscopic mucosal resection of short-segment Barrett's neoplasia.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity12442 :: ('MESH:C026285', 'Chemical') :: ['sucralose'] @entity384 :: ('MESH:D002311', 'Disease') :: ['Endoscopic dilation'] @entity4184 :: ('MESH:D019819', 'Chemical') :: ['budesonide'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['HGD', 'high grade dysplasia'] @entity420 :: ('MESH:D000230', 'Disease') :: ['early esophageal adenocarcinoma', 'EEA']
@entity4184 :: (MESH:D019819,Chemical) :: ['budesonide']
